ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced the Company has signed its 200th material transfer agreement (MTA) through its global ChromaDex External Research Program (CERP™). The program provides Niagen® (nicotinamide riboside) ingredient and placebos at no cost as well as technical expertise and intellectual property support to leading research institutions and universities around the world, advancing the evidence and understanding of the health impact of increa